Skip to main content

Advertisement

SpringerLink
Log in

Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial

  • Clinical Experience
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To explore the clinical effect and adverse reactions of Strychnos nux-vomica in bortezomib-induced peripheral neuropathy (BIPN) of patients with multiple myeloma (MM).

Methods

A total of 19 MM patients with BIPN were enrolled and Nux Vomica Capsule (NVC, 0.4 g, thrice daily) were orally administrated for 30 days. Comparative analysis on parameters between pre- and post-therapy, including peripheral neuropathy (PN) grade, neurotoxicity score, Chinese medicine (CM) syndrome score, total neuropathy score (TNS), coagulation function, and serum nerve growth factor (NGF) levels were conducted. The adverse events were monitored.

Results

In BIPN of MM patients who received NVC, PN grade was lowered, neurotoxicity score was obviously decreased (P⩽0.01), and both CM syndrome score and TNS were remarkably decreased (P<0.01). After the therapy, activated partial thromboplastin time was prolonged (P<0.01) and fibrinogen was declined (P<0.05), showing improvement in the hypercoagulable state of patients. No significant difference of NGF recovery degrees was detected between pre- and post-therapy (P>0.05). No evident adverse reactions were observed during the course of treatment.

Conclusion

Strychnos nux-vomica L. has significantly effect with a good safety in treatment of BIPN in MM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Cancer Netw 2009;7:908–942.

    Article  Google Scholar 

  2. Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009;69:859–888.

    Article  CAS  Google Scholar 

  3. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1593–1599.

    Article  CAS  Google Scholar 

  4. Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010;36 Suppl 2:S24–S32.

    Article  Google Scholar 

  5. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745–4753.

    Article  CAS  Google Scholar 

  6. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AL, Lopez de la Guia A, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012;120:2581–2588.

    Article  CAS  Google Scholar 

  7. Zhang Y, Wu W, Gu W. A clinical study of subcutaneous bortezomib in the treatment of multiple myeloma. Chin J Modern Drug Appl (Chin) 2016;6:161–162.

    Google Scholar 

  8. Arnulf B, Pylypenko H, Grosicki S, Karamanesht L, Leleu X, van de Velde H, et al. Updated survival analysis of a randomized phase M study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97:1925–1928.

    Article  Google Scholar 

  9. Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwing H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086–1095.

    Article  CAS  Google Scholar 

  10. Bao T, Goloubeva O, Pelser C, Porter NP, Primrose J, Hester LH, et al. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther 2014;13:396–404.

    Article  Google Scholar 

  11. National Pharmacopoeia Committee. Pharmacopoeia of People’s Republic of China. Part 1. Beijing: Chemical Industry Press; 2005.

    Google Scholar 

  12. Dong G, Hou Q, Pei J. An experimental study of grilled nux vomica in the treatment of rabbit model of myasthenia gravis. Chin J Tradit Med Sci Technol (Chin) 2005;12:3651.

    Google Scholar 

  13. Zhang Z, ed. Diagnostic and therapeutic effect criteria for hematological diseases. 3rd ed. Beijing: Science Press; 2007:232–233.

    Google Scholar 

  14. Multiple Myeloma Specialized Committee. Chinese expert consensus on diagnosis and treatment of multiple myeloma peripheral neuropathy 2015. Chin J Intern Med (Chin) 2015:54;821–824.

    Google Scholar 

  15. Qiu CL, Jin XL. Toxic reaction and premution of Strychnos nux-vomica L. in treating myasthenia gravis. Chin J Modern Appl Pharm (Chin) 1998;2:35.

    Google Scholar 

  16. Zhou J, Bian H, Ma C, Cai B, Wang T. Study on the antiplatelet aggregation and antithrombosis effects of strychnine and brucine N-oxide. Jiangsu J Tradit Chin Med (Chin) 1998;4(4):41–43.

    Google Scholar 

  17. Wang Y, Zhang LQ. Changlin’s experience in the treatment of flaccidity syndrome. J Tradit Chin Med (Chin) 2004;51:17–19.

    Google Scholar 

  18. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Version 4. Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997.

    Google Scholar 

  19. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman D, Hunt TL, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13:741–748.

    CAS  PubMed  Google Scholar 

  20. Chen XJ, Zhang BL. Internal medicine of traditional Chinese medicine. Beijing: Science Press; 2007:157–161.

    Google Scholar 

  21. Pang G, Yan Y, Zhu P. First draft of TCM diagnosis and treatment of diabetic peripheral neuropathy. China J Tradit Chin Med Pharm (Chin) 2010;25:260–264.

    Google Scholar 

  22. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12:210–215.

    Article  Google Scholar 

  23. Adverse Drug Reaction Evaluation Criteria. World Health Orgaization; 1979.

  24. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317–325.

    Article  CAS  Google Scholar 

  25. Gilmore TD, Garbati MR. Inhibition of NF-κB signaling as a strategy in disease therapy. Curr Top Microbiol Immunol 2011;349:245–263.

    CAS  PubMed  Google Scholar 

  26. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase M APEX study. J Clin Oncol 2008;26:4784–4790.

    Article  CAS  Google Scholar 

  27. Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011;96:1728–1732.

    Article  CAS  Google Scholar 

  28. Wang X, Li P. Pharmacological effects of nux vomica. Clin J Tradit Chin Med (Chin) 2008;20:198–200.

    Google Scholar 

  29. Qiu T, Chen M. Clinical observation of Nux Vomica Capsules in the treatment of 31 cases of myasthenia gravis. Chin J Tradit Chin Med Sci Technol (Chin) 2008;15:219–220.

    Google Scholar 

  30. Chen Q, Liu Y, Cui M, Han D, Bai Y, Su M, et al. Advances in study of in vivo processes and pharmacodynamic mechanism of nux vomica. Rheumat Arthrit (Chin) 2015;10:57–62.

    CAS  Google Scholar 

  31. Gao Y, Ye B, Zhou Y. Long-term therapeutic effect of grilled Nux Vomica Capsule plus autologous peripheral stem cell transplantation in the treatment of refractory myasthenia gravis. Modern J Integr Tradit Chin West Med (Chin) 2010;19:2341–2350.

    Google Scholar 

  32. Qian M, Hou Q, Pei J. An experimental study of grilled nux vomica plus hyperbaric oxygen treatment for rabbit spinal cord injury. Chin J Tradit Chin Med Sci Technol (Chin) 2009;16:182–183.

    Google Scholar 

  33. Zhang J, Xiao L, Dai T. Exploration of the analgesic effect of brucine and its mechanism. Chin J Tradit Chin Med Sci Technol (Chin) 2009;16:374–375.

    CAS  Google Scholar 

  34. Cao D, Liu Z, Yue L. Observation of the therapeutic effect of self-made Logan Tongbi Capsule in 60 cases of sciatica. Heilongjiang J Tradit Chin Med (Chin) 2007;50:17–18.

    Google Scholar 

  35. Xu X, Zhang X. A clinical study of Maomei Decoction plus vitamin B12 in the treatment of velcade-caused multiple myeloma peripheral neuropathy. Chin J Tradit Chin Med Sci Technol (Chin) 2012;19:13–14.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China

    Tie-ying Dai, Chu-chu Chen, Li-li Hong, Hang-ping Ge, Jun Pei, Wen-qi Lyu, Xue Yang, Jian-ping Shen & Zhi-ping Hu

Authors
  1. Tie-ying Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chu-chu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-li Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hang-ping Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Pei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wen-qi Lyu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xue Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian-ping Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zhi-ping Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dai TY, Shen JP, Qiu CL and Hu ZP conceived and designed the experiments. Chen CC, Lyu WQ, Ge HP, Pei J performed the experiments. Pei J, Hong LL, Yang X analyzed the data. Dai TY wrote the paper and Hu ZP revised the manuscript. All authors have reviewed the final manuscript.

Corresponding author

Correspondence to Zhi-ping Hu.

Ethics declarations

All authors declare that they have no any conflict of interests.

Additional information

Supported by Zhejiang Province Traditional Chinese Medicine Scientific Research Fund Project (No. 2015ZA094)

Supplementary material

11655_2020_3196_MOESM1_ESM.pdf

Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dai, Ty., Chen, Cc., Hong, Ll. et al. Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial. Chin. J. Integr. Med. 27, 131–136 (2021). https://doi.org/10.1007/s11655-020-3196-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-020-3196-2

Keywords

Search

Navigation